#CNT201 #Connext #Dupuytren's Contracture

Connext Achieves Dose Escalation Success in CNT201 Trial

Connext, a clinical-stage biotechnology firm, has reported a significant milestone in its clinical development of CNT201, a recombinant collagenase treatment for Dupuytren's contracture. The company has successfully completed the dose escalation phase of its Phase 1/2 clinical trial, marking an important step in its journey to provide new therapeutic options for this progressive hand condition.

Overview of the Clinical Trial

Conducted under an Investigational New Drug (IND) application cleared by the U.S. FDA, this trial follows an open-label design aimed at evaluating the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CNT201. Throughout this phase, no dose-limiting toxicities were observed, and the results indicate clear therapeutic benefits, showcasing CNT201’s potential as a viable treatment alternative.

The dose escalation phase not only confirmed the safety of the treatment but also showcased its efficacy, which bodes well for future phases.

Upcoming Phases and Expectations

Looking ahead, the second phase of the clinical trial is set to kick off in the third quarter of 2025. This phase will employ a double-blind study design to establish statistically significant therapeutic efficacy. Connext anticipates releasing top-line data for the entire Phase 1/2 trial by the first half of 2026, with plans for a global Phase 3 study to commence in 2027. Additionally, the latest developments regarding CNT201 are scheduled for presentation at the